Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells

Laryngoscope

Volumn 106, Issue 12, 1996, Pages 1471-1475

  Eicher, Susan A ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; RETINOIC ACID;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL LABELING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LEUKOPLAKIA; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 0029852626     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199612000-00005     Document Type: Article

References (41)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
2. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184-194.
3. Wendt CD, Peters LJ, Ang KK, et al. Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1989;17: 1057-1062.
4. Horiot JC, LeFur R, N'Guyen T, et al. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial. Eur J Cancer. 1990; 26:779-780.
5. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol. 1984;110:564-565.
6. Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991;20: 21-28.
7. Slaughter, DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer. 1953;6:963-968.
8. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol. 1994;12:851-873.
9. Hong WK, Lippman SM, Hittelman WN, et al. Retinoid chemoprevention of aerodigestive tract cancer: from basic research to the clinic. Clin Cancer Res. 1995;1:677-686.
10. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315: 1501-1505.
11. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.N Engl J Med. 1993;328:15-20.
12. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795-801.
13. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst. 1994;86:140-141.
14. Delia D. Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 1993;53:6036-6041.
15. Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995;55:853-861.
16. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 1979;39:1339-1346.
17. Moon RC, Pritchard JF, Mehta RG, et al. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis. 1989;10:1645-1649.
18. Moon RC, Mehta RG. Chemoprevention of experimental carcinogenesis in animals. Prev Med. 1989;18:576-591.
19. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991;51:3610-3611.
20. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993;53:224-226.
21. Rotmensz N, DePalo G, Formelli F, et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer. 1991;27:1127-1131.
22. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 1994;54(Suppl):2032s-2037s.
23. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem. 1993; 17F(Suppl):255-261.
24. Tradati N, Chiesa F, Rossi N, et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett. 1994;76:109-111.
25. Sacks PG, Parnes SM, Gallick GE, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res. 1988;48:2858-2866.
26. Kopan R, Traska G, Fuchs E. Retinoids as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol. 1987;105:427-440.
27. Mehta RG, Costa A, Formelli F, et al. Metabolism of N-(4-hydroxyphenyl)retinamide (4HPR) in human breast tissues. Fed Am Soc Exp Biol J. 1988;2:A1095.
28. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol. 1993;11:2036-2042.
29. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
30. Gregoire V, Van TN, Stephens C, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res. 1994;54:6201-6209.
31. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol. 1990;79:448-453.
32. Atencia R, Garcia-Sanz M, Unda F, et al. Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Exp Cell Res. 1994;214:663-667.
33. Toma S, Losardo PL, Vincent M, et al. Effectiveness of β-carotene in cancer chemoprevention. Eur J Cancer Prev. 1995;4:213-224.
34. Garewal H. Chemoprevention of oral cancer: β-carotene and Vitamin E in leukoplakia. Eur J Cancer Prev. 1994;3:101-107.
35. Oridate N, Lotan D, Mitchell MF, et al. Induction of apoptosis by retinoids in human cervical carcinoma cell lines. Int J Oncol. 1995;7:433-441.
36. Muindi J, Frankel SR, Miller WH, Jr, et al. Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992;79:299-303.
37. Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood. 1993;82:2175-2181.
38. El-Naggar AK, Hurr K, Batsakis JG, et al. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res. 1995;55:2656-2659.
39. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54:321-326.
40. El-Naggar AK, Lai S, Luna MA, et al. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer. 1995;64:196-201.
41. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Genet Dev. 1994;4:120-129.